Dyne Therapeutics (NASDAQ:DYN) Upgraded by StockNews.com to Hold

StockNews.com upgraded shares of Dyne Therapeutics (NASDAQ:DYN) from a sell rating to a hold rating in a research report report published on Saturday morning.

Other equities research analysts also recently issued reports about the company. Oppenheimer reiterated an outperform rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a report on Monday, May 6th. Piper Sandler increased their price objective on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the company an overweight rating in a research report on Tuesday, August 13th. Jefferies Financial Group lifted their target price on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the stock a buy rating in a research report on Monday, May 20th. Stifel Nicolaus increased their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the company a buy rating in a report on Friday, August 16th. Finally, Morgan Stanley upped their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the company an overweight rating in a research report on Wednesday, August 14th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of Buy and a consensus price target of $50.60.

Dyne Therapeutics Price Performance

DYN opened at $46.82 on Friday. The firm has a market cap of $4.09 billion, a PE ratio of -11.79 and a beta of 1.07. The stock has a 50-day moving average price of $39.51 and a 200-day moving average price of $31.33. Dyne Therapeutics has a 1 year low of $6.40 and a 1 year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.02. As a group, sell-side analysts anticipate that Dyne Therapeutics will post -3 EPS for the current year.

Insiders Place Their Bets

In related news, COO Susanna Gatti High sold 80,000 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $30.24, for a total value of $2,419,200.00. Following the sale, the chief operating officer now owns 154,062 shares in the company, valued at $4,658,834.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Oxana Beskrovnaya sold 2,136 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $31.34, for a total value of $66,942.24. Following the completion of the sale, the insider now directly owns 147,511 shares of the company’s stock, valued at approximately $4,622,994.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Susanna Gatti High sold 80,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $30.24, for a total value of $2,419,200.00. Following the transaction, the chief operating officer now directly owns 154,062 shares in the company, valued at approximately $4,658,834.88. The disclosure for this sale can be found here. Insiders have sold a total of 163,676 shares of company stock valued at $5,270,510 in the last quarter. 20.77% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Federated Hermes Inc. bought a new position in Dyne Therapeutics in the 4th quarter valued at $4,988,000. Concurrent Investment Advisors LLC purchased a new stake in shares of Dyne Therapeutics during the first quarter valued at $573,000. Sei Investments Co. bought a new position in shares of Dyne Therapeutics in the first quarter worth about $693,000. Rafferty Asset Management LLC increased its stake in Dyne Therapeutics by 17.7% in the 4th quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock worth $2,182,000 after buying an additional 24,632 shares during the period. Finally, Commodore Capital LP bought a new stake in Dyne Therapeutics during the 4th quarter valued at about $11,970,000. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.